Maintenance therapy with 5-fluoruracil/leucovorin (5FU/LV) plus panitumumab (pmab) or 5FU/LV alone in RAS wildtype (WT) metastatic colorectal cancer (mCRC) - the PANAMA trial (AIO KRK 0212).

Dominik Paul Modest,Meinolf Karthaus,Stefan Frühauf,Ullrich Graeven,Lothar Müller,Alexander Koenig,Ludwig Fischer von Weikersthal,Karel Caca,Albrecht Kretzschmar,Eray Goekkurt,Siegfried Haas,Annika Kurreck,Arndt Stahler,Volker Heinemann,Swantje Held,Armin Jarosch,David Horst,Stefan Kasper,Sebastian Stintzing,Tanja Trarbach

Maintenance therapy with 5-fluoruracil/leucovorin (5FU/LV) plus panitumumab (pmab) or 5FU/LV alone in RAS wildtype (WT) metastatic colorectal cancer (mCRC) - the PANAMA trial (AIO KRK 0212).

2021

3503Background: Planned discontinuation or stop-and-go use of oxaliplatin are established strategies in the systemic therapy of mCRC. Consequently, and irrespective of antibody use, 5FU/LV represen...

Keywords:

Systemic therapy
Medicine
Oxaliplatin
Internal medicine
Discontinuation
Colorectal cancer
Oncology
Panitumumab
Maintenance therapy
Antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations